BioCryst Pharmaceuticals, Inc. (BCRX)

9.10 +0.07 (+0.78%) As of 04:00PM EDT. Market open.

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 358

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jon P. Stonehouse	CEO, Pres & Exec. Director	1.14M	N/A	1961
Mr. Anthony J. Doyle	Sr. VP & CFO	745.79k	N/A	1980
Dr. William P. Sheridan	Chief Medical Officer & Sr. VP	843.42k	1.89M	1955
Dr. Yarlagadda S. Babu	Chief Discovery Officer	698.33k	831.93k	1953
Dr. Helen M. Thackray FAAP, M.D.	Chief R&D Officer	966.38k	N/A	1968
Mr. Michael L. Jones	Exec. Director of Fin. & Principal Accounting Officer	N/A	N/A	1970
Ms. Alane P. Barnes	Sr. VP, Chief Legal Officer & Corp. Sec.	N/A	N/A	1966
Mr. John D. Bluth	Chief Communications Officer	N/A	N/A	1973
Ms. Stephanie Angelini	Chief People Officer	N/A	N/A	N/A
Dr. Elliott T. Berger	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate governance

BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2022 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.